The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
De GrootJFLambronKRChangSM. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2011; 29(19);2689–2695.
2.
IsambertNFreyerGZanettaS. Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res.2012;18(6):1743–1750.
3.
LeighlNBRaezLEBesseB. A multicenter, phase 2 study of vascular endothelial growth factor trap (aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol.2010;5(7):1054–1058.
4.
LockhartACRothenbergMLDupontJ. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol.2010;28(2):207–214.
5.
TarhiniAAFrankelPMargolinKA. Aflibercept (VEGF trap) in inoperable stage III or stage IV melanoma of cutaneous or uveal origin. Clin Cancer Res.2011;17(20):6574–6581.
6.
ColemanRLDuskaLRRamirezPT. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol.2011;12(12):1109–1117.
7.
ColomboNMangiliGMammolitiS. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol Oncol.2012;125(1):42–47.
8.
GotleibWHAmantFAdvaniS. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomized, double-blind placebo-controlled study. Lancet Oncol.2012;13(2):154–162.
9.
TwardowskiPStadlerWMFrankelP. Phase II study of aflibercept (VEGF-trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium trial. Urology. 2010;76(4):923–926.
10.
FreyerGIsambertNYouB. Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumors. Br J Cancer.2012;107(4):598–603.
11.
Diaz-PadillaISiuLLPedro-SalcedoMS. A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumors. Br J Cancer.2012;107(4):604–611.
12.
Wang-GillamATewWPRothenbergML. A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors. Invest New Drugs.2012;30(5):1958–1961.
RodriguezMAPytlikRKozakT. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma. Cancer. 2009;115(15):3475–3482.
15.
ThomasDASarrisAHCortesJ. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer.2006;106(1):120–127.
16.
ThomasDAKantarjianHMStockW. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer.2009;115(23):5490–5498.
17.
SarrisAHHagemeisterFRomagueraJ. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol.2000;11(1):69–72.
18.
GelmonKATolcherADiabAR. Phase I study of liposomal vincristine. J Clin Oncol.1999;17(2):697–705.
19.
BedikianAYSilvermanJAPapadopoulosNE. Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function. J Clin Pharmacol. 2011;51(8):1205–1212.
20.
BedikanAYVardeleonASmithT. Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients. J Clin Pharmacol. 2006;46(7):727–737.
21.
Marqibo [package insert]. South San Francisco, CA: Talon Therapeutics, Inc; 2012. http://www.marqibo.com/. Accessed September 17, 2012.
